
Colleen Tracy James and Neil DuChez ask, is biosimilar litigation the new frontier as predicted or an area pursued less vigorously as under the Hatch-Waxman Act because of cost and manufacturing obstacles?
Colleen Tracy James is a partner and Neil DuChez an associate, both in the intellectual property group of Mayer Brown LLP.
Published: April 11th 2015 | Updated: